Medmira Inc (TSE:MIR) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Medmira Inc. reports a significant corporate milestone with the US FDA 510(k) clearance for its Reveal G4 Rapid HIV-1/2 antibody test, set to bolster its U.S. market share and revenues. The company also completed supporting studies for Health Canada and expanded its Commercialisation Department, aiming to strengthen its North American presence. Despite these advancements, Medmira experienced a net loss of $590,789 this quarter, with a slight increase in working capital deficit.
For further insights into TSE:MIR stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue